How can I educate parents on preventing and managing respiratory syncytial virus (RSV) in infants, especially those under 6 months, premature, or with chronic lung or heart disease, including prophylaxis with intramuscular palivizumab, warning signs that require urgent care, and appropriate home care measures?

Parent Education for RSV Prevention and Management

Prevention Through Prophylaxis: Who Qualifies

Nirsevimab (Beyfortus) is now the first-line prophylactic agent for RSV, replacing palivizumab for most infants. 1

Universal Prophylaxis Recommendations

• All infants younger than 8 months entering their first RSV season should receive a single dose of nirsevimab, regardless of gestational age or underlying conditions 1
• Nirsevimab provides season-long protection with just one intramuscular injection (50 mg for infants <5 kg; 100 mg for infants ≥5 kg), eliminating the need for monthly visits 1
• This represents a major shift from the previous palivizumab approach, which was restricted to only ~5% of high-risk infants 1

High-Risk Children in Second RSV Season

• Children aged 8-19 months with increased risk entering their second RSV season should receive nirsevimab (200 mg as two separate 100 mg injections) 1
• High-risk conditions include: chronic lung disease requiring ongoing therapy, hemodynamically significant congenital heart disease, severe immunocompromise, or cystic fibrosis with severe lung manifestations 1

When Palivizumab May Still Be Used

• Palivizumab remains an option only when nirsevimab is unavailable or inappropriate 1
• If palivizumab is used, administer 15 mg/kg intramuscularly monthly throughout RSV season (maximum 5 doses) 2, 3
• Never administer both nirsevimab and palivizumab to the same infant 1

Alternative: Maternal Vaccination

• Pregnant individuals may receive RSVpreF vaccine (Abrysvo) as a one-time dose at 32-36 weeks' gestation for infant protection 1
• Important caveat: Either maternal vaccination OR infant nirsevimab is recommended—not both for most infants 1

Essential Non-Pharmacologic Prevention Measures

Environmental Protection

• Completely eliminate tobacco smoke exposure—this is a controllable risk factor that significantly increases RSV hospitalization risk 2, 1, 4
• Keep high-risk infants away from crowds and situations where exposure to infected people cannot be controlled 2
• Restrict participation in group childcare during RSV season (typically November through April) for high-risk infants whenever feasible 2

Hand Hygiene: The Single Most Important Measure

• Hand decontamination before and after contact with the infant is the most critical step in preventing RSV transmission 2, 4
• Use alcohol-based hand rubs as the preferred method when hands are not visibly soiled 2, 4
• Educate all family members, visitors, and caregivers on proper hand hygiene technique 2, 4

Breastfeeding and Immunizations

• Encourage breastfeeding to potentially decrease the risk of lower respiratory tract disease 2, 4
• Ensure influenza vaccination for all infants ≥6 months and all household contacts starting when the child is born 2
• Maintain all age-appropriate routine immunizations on schedule 2

Warning Signs Requiring Urgent Medical Care

Respiratory Distress Indicators

• Oxygen saturation falling below 90% on room air requires immediate emergency department evaluation 4
• Increased work of breathing: visible chest retractions, flaring nostrils, or grunting sounds 4
• Rapid breathing that doesn't improve with rest 4
• Difficulty breathing or appearing to struggle to breathe 4

Systemic Warning Signs

• Lethargy, difficulty waking, or altered mental status are severe symptoms requiring prompt evaluation 4
• Inability to maintain adequate oral fluid intake or signs of dehydration 2
• Persistent fever in infants, especially those under 3 months of age 2

Special Populations at Higher Risk

• Premature infants (especially ≤28 weeks gestation) require closer monitoring as oxygen is weaned 2
• Infants with hemodynamically significant heart or lung disease need vigilant observation for any respiratory changes 2
• Infants with neuromuscular disorders that impair secretion clearance are at increased risk for severe disease 1

Home Care Management

Supportive Care is the Only Evidence-Based Treatment

• There is no effective antiviral or disease-modifying therapy for RSV in children—treatment is entirely supportive 5
• Do not use bronchodilators, corticosteroids, or antibiotics routinely, as they have no proven benefit in typical RSV infection 2, 5, 4

Hydration and Nutrition

• Assess the infant's ability to take fluids orally and monitor hydration status closely 2, 4
• Offer frequent small feedings to maintain adequate fluid intake 2
• If the infant cannot maintain hydration orally, seek medical attention for possible intravenous or nasogastric fluid administration 2

Symptom Management

• Use acetaminophen or ibuprofen (age-appropriate) for fever or discomfort 4
• Nasal saline irrigation may provide symptomatic relief for upper respiratory congestion 4
• Suction the infant's nose gently if secretions are interfering with feeding or breathing 2

Oxygen Monitoring

• Supplemental oxygen should only be administered if oxygen saturation persistently falls below 90% 2, 5, 4
• Continuous pulse oximetry at home is not routinely necessary as the child's clinical course improves 2

Common Pitfalls to Avoid

Prophylaxis Misconceptions

• Palivizumab has no therapeutic benefit for treating established RSV infection—it is only for prevention 1, 5, 4
• Do not discontinue prophylaxis prematurely before the end of RSV season 1
• If a child receives palivizumab and develops breakthrough RSV infection, discontinue further palivizumab doses (likelihood of second RSV hospitalization same season is <0.5%) 1

Treatment Errors

• Avoid overuse of antibiotics when there is no evidence of bacterial co-infection 4
• Do not continue bronchodilator therapy without documented clinical improvement 4
• Recognize that ribavirin is restricted to severely immunocompromised patients and mechanically ventilated infants with documented severe RSV—not for routine use 4

Infection Control Failures

• Inadequate hand hygiene is the most common cause of RSV transmission in households 4
• Allowing visitors with respiratory symptoms to have contact with the infant significantly increases infection risk 4
• RSV can survive on countertops for ≥6 hours and on skin for up to 20 minutes, emphasizing the need for environmental cleaning 4